| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ARQT | Common Stock | Sale | -$661K | -44.2K | -26.58% | $14.97 | 122K | Mar 13, 2025 | Direct | F1, F2 |
| transaction | ARQT | Common Stock | Options Exercise | $0 | +5.01K | +4.11% | $0.00 | 127K | Mar 13, 2025 | Direct | F3 |
| transaction | ARQT | Common Stock | Sale | -$75.6K | -5.01K | -3.95% | $15.10 | 122K | Mar 13, 2025 | Direct | F3, F4 |
| transaction | ARQT | Common Stock | Options Exercise | $0 | +12.2K | +10.04% | $0.00 | 134K | Mar 14, 2025 | Direct | F3 |
| transaction | ARQT | Common Stock | Sale | -$184K | -12.2K | -9.12% | $15.04 | 122K | Mar 14, 2025 | Direct | F3, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ARQT | Stock Option (right to buy) | Options Exercise | $0 | -5.01K | -2.29% | $0.00 | 213K | Mar 13, 2025 | Common Stock | 5.01K | $3.64 | Direct | F3 |
| transaction | ARQT | Stock Option (right to buy) | Options Exercise | $0 | -12.2K | -5.73% | $0.00 | 201K | Mar 14, 2025 | Common Stock | 12.2K | $3.64 | Direct | F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. |
| F2 | The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.6545 to $15.35, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| F3 | On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. |
| F4 | The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.34, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.1429, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Reporting Person's title: Executive Vice President, Chief Medical Officer